SJSA-1 / SJSA-1-luc Orthotopic Mouse Model Service for Sarcoma

The SJSA-1 / SJSA-1-luc orthotopic mouse model for sarcoma is a human osteosarcoma xenograft platform built on a genetically distinctive foundation — MDM2 amplification with wild-type TP53 — in which tumor cells are grafted into the bone of immunodeficient mice to enable p53-reactivation therapy, resistance-emergence, and bone-lesion studies. Alfa Cytology delivers this model as a complete preclinical capability — spanning authenticated SJSA-1 / SJSA-1-luc expansion and luciferase-stable banking, precision intraosseous implantation, scheduled in vivo bioluminescence tracking of primary bone tumors, and complete skeletal histopathology with pharmacodynamic p53-pathway readouts — all configured around each sponsor’s mechanism of action and endpoint plan.

Overview of SJSA-1 / SJSA-1-luc Orthotopic Mouse Model for Sarcoma

SJSA-1 occupies a special position among osteosarcoma models because of a single defining abnormality: the MDM2 gene is amplified roughly 45-fold, flooding the cell with the E3 ubiquitin ligase that tags p53 for degradation, while TP53 itself remains wild-type. Established in 1982 from the primary tumor of an 18-year-old male with osteosarcoma, the line therefore represents the classic clinical scenario in which p53 is functionally silenced not by mutation but by overexpression of its negative regulator — a phenotype estimated to occur in a substantial fraction of sarcomas. This genotype makes SJSA-1 the reference system for p53-reactivation pharmacology: among a panel of ten cancer cell lines it showed the strongest apoptotic response to MDM2 antagonists, precisely because MDM2 amplification appears to be the principal defect in its p53 pathway. The line additionally carries an NRAS Q61K mutation, making it a useful substrate for MAPK-pathway studies, and it grows well in both culture and immunodeficient hosts.

Fig 1. Genomic correlation matrix (heatmap) of osteosarcoma PDX cell lines and patient samples, with SJSA as reference cell line in the cohort. (Schott, Courtney R., et al., 2024)

In animals, SJSA-1 has produced some of the most dramatic proof-of-concept results in the MDM2-inhibitor field. Early work showed that nutlin-3 at 200 mg/kg twice daily for 20 days inhibited tumor growth in nude mice without apparent systemic toxicity, while optimized antagonists went further: RG7112 produced dose-dependent tumor regression, RG7388 at 25 mg/kg oral daily achieved outright tumor regression, and SAR405838 induced rapid, complete, and durable tumor regression — then, tellingly, treated tumors that eventually regrew yielded sublines that have become the standard reagents for studying how resistance emerges under p53-pathway pressure, both in vitro and in vivo. Locating this biology in the bone amplifies its translational relevance: orthotopic bioluminescent osteosarcoma xenograft methodology is established in Swiss nude and NSG mice, and the luciferase-labeled derivative SJSA-1-luc allows tumor take and growth in the operated limb to be tracked longitudinally by in vivo imaging, with micro-CT and histopathology confirming bone involvement. The result is a platform where p53-reactivation agents, MAPK-pathway inhibitors, and combination regimens can be evaluated with both imaging readouts and mechanism-resolving pharmacodynamic endpoints.

Cell Line Information: SJSA-1 / SJSA-1-luc

The table below consolidates the key biological, cultural, and modeling characteristics of the SJSA-1 parental line and its luciferase-labeled derivative SJSA-1-luc. Both are human-derived and require immunodeficient hosts for in vivo work.

Our Services

Few models reward mechanistic rigor the way MDM2-amplified osteosarcoma does, and Alfa Cytology runs the SJSA-1 / SJSA-1-luc orthotopic program accordingly: authenticated cell banks, standardized intraosseous implantation, weekly in vivo bioluminescence with micro-CT correlation, and endpoint pathology paired with p53-pathway pharmacodynamics — all under one accountable preclinical operation.

Workflow of SJSA-1 / SJSA-1-luc Orthotopic Mouse Model Construction

Construction follows established intraosseous bioluminescent xenograft methodology as validated in Swiss nude and NSG mice: luciferase-labeled SJSA-1 cells are expanded under authenticated conditions, concentrated into a small-volume suspension, injected into the proximal tibial medullary cavity, and followed by serial imaging with bone-focused, mechanism-resolving endpoint analysis. The workflow comprises the following stages.

1. Cell authentication and banking: SJSA-1 or SJSA-1-luc cells are verified by STR profiling, confirmed mycoplasma-free, and expanded into low-passage working banks under standardized RPMI-1640 culture conditions.
2. Cell harvest and formulation: Exponentially growing cultures are trypsinized, washed, counted and viability-checked, then resuspended at approximately 1 × 10⁶ cells in 10–20 μL of PBS or a Matrigel-supported suspension and kept on ice until implantation.
3. Anesthesia and tibial access: Male immunodeficient mice are anesthetized with isoflurane, the proximal tibia is exposed through a small skin incision, and a fine-gauge needle enters the medullary cavity at the tibial plateau.
4. Orthotopic implantation: The cell suspension is slowly injected into the proximal tibial cavity; the needle is held briefly after injection to limit reflux along the cortical tract and standardize take rates.
5. Closure and perioperative care: The puncture site is sealed, the skin is closed, and animals receive analgesia with close post-operative monitoring, including gait observation for lameness and limb swelling.
6. Engraftment confirmation and serial imaging: Luciferin is administered intraperitoneally and bioluminescence is acquired to confirm tibial tumor take and normalize group allocation; imaging repeats on a weekly cadence to track primary lesion growth and response.
7. Intervention and endpoint analysis: Experimental arms — MDM2 antagonists, MAPK-pathway inhibitors, combination chemotherapy, and sequencing regimens — proceed per study design; endpoints integrate imaging with radiography and micro-CT (bone architecture), tumor-bearing limb dissection and weighing, and histopathology (H&E with Ki67, TRAP, p53/MDM2/p21 pharmacodynamic staining, and marker-specific immunohistochemistry).

Fig 2. SJSA-1 / SJSA-1-luc orthotopic mouse model construction workflow.

Case Study-SJSA-1 / SJSA-1-luc Orthotopic Mouse Model Development

Alfa Cytology has conducted preclinical programs on the SJSA-1 / SJSA-1-luc orthotopic platform spanning MDM2-p53 inhibitor efficacy and pharmacodynamic assessment, MAPK-pathway agent evaluation, and treatment-emergent resistance investigation. In these studies, intraosseously implanted SJSA-1-luc tumors were quantified longitudinally by in vivo bioluminescence, with bone architecture, tumor histopathology, and p53-pathway biomarker changes characterized at endpoint. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology combines mechanism-driven study design with integrated surgical, imaging, and pathology execution, so every SJSA-1 / SJSA-1-luc orthotopic study delivers both quantitative efficacy data and mechanism-resolving pharmacodynamic evidence.

• Deep familiarity with MDM2-amplified, TP53 wild-type models and p53-reactivation study designs, including resistance-emergence workflows.
• A single coordinated team managing cell banking, tibial implantation surgery, in vivo imaging, micro-CT, and endpoint pathology under one quality framework.
• Longitudinal bioluminescence readouts enabling precise quantification of tumor response and regrowth kinetics.
• Endpoint pharmacodynamic panels (p53, MDM2, p21, Ki67, apoptosis markers) paired with skeletal histopathology.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your sarcoma program targets the p53-MDM2 axis, MAPK signaling, or osteosarcoma bone disease, Alfa Cytology is ready to build the study around your mechanism. Reach out to us with your compound profile and endpoint needs, or contact us today for a customized proposal and quotation for the SJSA-1 / SJSA-1-luc orthotopic mouse model service.

For research use only. Not intended for any clinical use.